Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05756621Recruiting

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Role: collaborator

NCT06981377Recruiting

PRostate Cancer Plasma Integrative Multi-modal Evaluation

Role: lead

NCT06783127Recruiting

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Role: lead

NCT06473259Recruiting

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Role: lead

NCT02453009Phase 2Completed

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

Role: lead

NCT02350413Completed

Multicenter Italian Validation of EHP-30

Role: collaborator

NCT01138540Phase 3Terminated

The Gravity-VAP (Ventilator-Associated Pneumonia) Trial

Role: collaborator

NCT01046994Phase 3Unknown

Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion

Role: collaborator

All 8 trials loaded